VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Rating of “Reduce” by Analysts

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has earned an average recommendation of “Reduce” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $0.95.

Several brokerages recently commented on VTGN. Wall Street Zen downgraded shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Jefferies Financial Group restated a “hold” rating and issued a $0.90 target price (down previously from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target on the stock. in a report on Wednesday, December 17th. Maxim Group reissued a “hold” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, January 21st.

Institutional Investors Weigh In On VistaGen Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AdvisorShares Investments LLC raised its holdings in shares of VistaGen Therapeutics by 27.7% during the second quarter. AdvisorShares Investments LLC now owns 203,114 shares of the company’s stock worth $406,000 after acquiring an additional 44,000 shares in the last quarter. Millennium Management LLC acquired a new position in VistaGen Therapeutics in the 3rd quarter worth about $73,000. Bank of America Corp DE raised its stake in shares of VistaGen Therapeutics by 926.0% during the 3rd quarter. Bank of America Corp DE now owns 34,657 shares of the company’s stock worth $123,000 after purchasing an additional 31,279 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of VistaGen Therapeutics during the 3rd quarter worth about $39,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of VistaGen Therapeutics during the 3rd quarter valued at about $152,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Stock Up 1.4%

VTGN opened at $0.57 on Thursday. The firm has a market cap of $22.61 million, a PE ratio of -0.30 and a beta of 0.32. The business has a fifty day simple moving average of $1.32 and a 200-day simple moving average of $2.84. VistaGen Therapeutics has a fifty-two week low of $0.50 and a fifty-two week high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last announced its earnings results on Thursday, November 13th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The firm had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.16 million. On average, equities research analysts anticipate that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

More VistaGen Therapeutics News

Here are the key news stories impacting VistaGen Therapeutics this week:

• Positive Sentiment: Short interest fell ~16.6% in January to ~2.04M shares (5.3% of float), reducing short-pressure and removing a potential source of downside volatility for VTGN. (data release)
• Positive Sentiment: At least one brokerage published a $0.95 price target, which is above the current trading level and can support upside sentiment. Brokerages Set VistaGen Therapeutics, Inc. (NASDAQ:VTGN) PT at $0.95
• Neutral Sentiment: An earnings preview highlights VTGN’s upcoming Q3 2026 results — an event that could swing the stock either way depending on topline, cash-burn and guidance vs. expectations. Traders often reprice biotechs around quarterly updates. Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2026 Result
• Negative Sentiment: Multiple law firms have filed or announced shareholder class actions and lead-plaintiff deadline reminders covering purchases between April 1, 2024 and Dec 16, 2025; these filings can pressure the stock via litigation risk, potential settlements and legal costs. Representative filings/alerts include The Gross Law Firm. The Gross Law Firm Notifies Vistagen Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – VTGN
• Negative Sentiment: Rosen Law Firm has issued reminders encouraging investors to seek counsel and observe a March 16, 2026 lead plaintiff deadline — repeated notices increase visibility of litigation risk. ROSEN, LEADING INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTGN
• Negative Sentiment: Faruqi & Faruqi issued a shareholder reminder about the March 16 deadline and its investigation into potential claims, reinforcing the same litigation narrative and keeping the story in front of retail holders. VTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
• Negative Sentiment: Levi & Korsinsky announced a securities class action filed against VistaGen, which may elevate perceived liability and increase downside risk until the litigation outcome becomes clearer. LEVI & KORSINSKY, LLP ANNOUNCES SECURITIES CLASS ACTION FILED AGAINST VISTAGEN THERAPEUTICS UNDER FEDERAL SECURITIES LAWS
• Negative Sentiment: Bernstein Liebhard and the Schall Law Firm also announced or notified investors about securities fraud class actions, adding to the cluster of litigation notices and keeping legal risk top of mind for investors. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
• Negative Sentiment: Schall Law Firm reminder gives investors another avenue to seek lead-plaintiff status, maintaining pressure and media attention around potential litigation exposures. VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.